Hydroxychloroquine (HCQ) is known as a drug to treat malaria. However, the drug is also used in the treatment of some dermatological diseases such as Lupus erythematosus, Porphyria cutanea tarda and some other conditions. The following article provides readers with some information about the effects of Hydroxychloroquine in the treatment of dermatological diseases and notes when using it.

Dermatomyositis is a disease with muscle inflammation accompanied or not by skin lesions. Polymyositis is an autoimmune disease and responds to immunosuppressive drugs. The disease can appear at any age, usually in adolescence (10-15 years old) and middle age (45-60 years old), women are more affected than men. The incidence of polymyositis in the community is estimated at 5-10 cases/1 million people.

Autoimmune diseases account for about 3-5% of the population due to the formation of autoimmune antibodies against organ tissue components including cell nucleus, cytoplasm, cell membrane... Therefore, testing to find the circulation of autoimmune antibodies in immune diseases is very necessary, in which the soluble antigen antibody test is often done after a positive ANA test to detect autoimmune diseases.

Dermatomyositis is a systemic autoimmune disease that causes inflammation of the muscles or related tissues, such as the skin or blood vessels that supply the muscles. The disease causes inflammatory reactions, cell damage, loss of motor function and many other dangerous complications if not detected and controlled properly from the beginning.